SuRo Capital Portfolio Investment, CoreWeave, Completes Largest Tech IPO Since 2021 SuRo Capital Portfolio Investment, OpenAI, Closes Largest Venture Raise with $300 Billion Valuation Net Asset Value of $6.66 Per Share as of March 31, 2025 NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- SuRo Capital Corp. (“SuRo Capital”, the “Company”, “we”, “us”, and “our”) (Nasdaq: SSSS) today announced its financial results for the first quarter ended March 31, 2025. Net assets totaled approximately $156.8 million, or $6.66 ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (together with its consolidated subsidiaries, “we,” “us,” “our,” “CGBD” or the “Company”) (NASDAQ: CGBD) today announced its financial results for its first quarter ended March 31, 2025. Justin Plouffe, CGBD’s Chief Executive Officer, said, “Following successful completion of the merger with CSL III at the end of March, CGBD remains focused on driving stable income, consistent credit performance, and disciplined execution of our strate ...

Core Viewpoint - Motorsport Games Inc. is scheduled to report its financial results for the first quarter of 2025 on May 9, 2025, after market close, followed by a conference call to discuss the results [1][6]. Company Overview - Motorsport Games is a developer and publisher of racing games and an esports ecosystem provider for official motorsport racing series, aiming to create authentic racing experiences [3]. - The company holds licenses for prominent racing series such as the 24 Hours of Le Mans and the FIA World Endurance Championship, with recent releases including Le Mans Ultimate in Early Access [3]. - Motorsport Games owns the rFactor 2 and KartKraft simulation platforms and powers F1® Arcade through a partnership with Kindred Concepts [3]. - The company is recognized as an award-winning esports partner for the 24 Hours of Le Mans, having established the Le Mans Virtual Series [3]. Financial Reporting Details - The financial results will be discussed in a conference call and webcast on May 9, 2025, at 5:00 p.m. ET, accessible via the company's investor relations website and by phone [1][2].

Core Viewpoint - Weyco Group, Inc. reported a decline in financial performance for the first quarter of 2025, with net sales down 5% compared to the same period in 2024, primarily due to lower sales across major brands and reduced consumer spending on non-athletic footwear [3][11]. Financial Performance - Net sales for the first quarter of 2025 were $68.0 million, down from $71.6 million in Q1 2024 [11]. - Gross earnings as a percentage of net sales were 44.6%, slightly down from 44.7% in Q1 2024 [11]. - Earnings from operations decreased by 15% to $7.0 million compared to $8.3 million in Q1 2024 [11]. - Net earnings fell by 17% to $5.5 million from $6.7 million in the previous year [11]. - Diluted earnings per share decreased to $0.57 from $0.69 in Q1 2024 [11]. Segment Performance North American Wholesale Segment - Wholesale net sales were $54.3 million, a 4% decrease from $56.2 million in Q1 2024 [3]. - Florsheim's sales increased by 7% due to new product launches, but this was offset by declines in other brands: Stacy Adams down 7% and Nunn Bush down 16% [3]. - Wholesale operating earnings decreased by 10% to $6.6 million from $7.4 million in 2024 [4]. North American Retail Segment - Retail segment net sales were $8.7 million, down 12% from $9.8 million in 2024 [5]. - Retail operating earnings fell by 52% to $0.6 million from $1.3 million in the previous year [6]. Other Operations - Florsheim Australia reported net sales of $5.1 million, down 7% from $5.5 million in Q1 2024, impacted by a weaker Australian dollar [8]. - In local currency, net sales in Australia increased by 6%, with higher sales in both wholesale and retail [8][9]. Tariff Impact - The effective total tariff rate on goods sourced from China has risen to 161% from 16% in 2024, which may significantly increase future costs of goods sold [10]. - The company has negotiated cost reductions with several Chinese suppliers to mitigate the impact of these tariffs [10][12]. Dividend Declaration - The Board of Directors declared a quarterly cash dividend of $0.27 per share, a 4% increase from the previous rate of $0.26 [14]. Conference Call - A conference call is scheduled for May 7, 2025, to discuss the first quarter 2025 financial results in detail [15].

Financial Performance - The company reported total revenue of $42.2 million for the first quarter of 2025, a decrease from $43.0 million in the prior year period, primarily due to the expiration of a customer contract in December 2024, despite a 3.3% growth in cloud subscribers year-over-year [5][6]. - Quarterly recurring revenue constituted 93.1% of total revenue, an increase from 91.1% in the prior year period [6]. - Gross profit increased by 3.4% to $29.7 million, resulting in a gross margin of 70.4%, compared to 66.9% in the prior year [6]. - Adjusted gross profit rose by 1.7% to $33.4 million, with an adjusted gross margin of 79.0%, up from 76.3% in the prior year [6]. - The company reported a net loss of $3.8 million, or $(0.37) per diluted share, compared to a net income of $4.5 million, or $0.23 per diluted share, in the prior year period [6][23]. - Adjusted EBITDA increased by 17.0% to $12.7 million, with an adjusted EBITDA margin of 30.2%, compared to 25.4% in the prior year [6][23]. Operational Highlights - The company successfully executed a $200 million term loan refinancing, extending debt maturity until 2029, which strengthens its capital structure and provides anticipated financial stability [3][5]. - The company reaffirmed its full-year guidance metrics, indicating confidence in achieving its financial targets despite a volatile global economy [3][7]. Cash Flow and Liquidity - Cash and cash equivalents were reported at $29.1 million as of March 31, 2025, down from $33.4 million as of December 31, 2024 [6][21]. - Free cash flow for the first quarter was $(3.0) million, compared to $(3.3) million in the prior year period, indicating a consistent cash spend during this historically heavy cash outflow period [6][26]. 2025 Financial Outlook - The company reiterated its full-year revenue guidance range of between $170 million and $180 million, with recurring revenue expected to be at least 90% of total revenue [11]. - Adjusted gross margin is projected to be between 78% and 80%, and adjusted EBITDA is expected to be between $52 million and $56 million, equating to at least a 30% adjusted EBITDA margin [11]. - Free cash flow is anticipated to be between $11 million and $16 million, excluding the expected federal tax refund of approximately $28 million plus applicable interest [11].

Core Insights - Denali Therapeutics has completed the Biologics License Application (BLA) submission for tividenofusp alfa, marking a significant milestone in its development as a late-stage commercial organization focused on treating Hunter syndrome [2][3] - The company is preparing for the commercial launch of tividenofusp alfa, expected in late 2025 or early 2026, which would be the first FDA-approved enzyme replacement therapy designed to cross the blood-brain barrier [2][3] - Denali's clinical pipeline includes ongoing programs for Sanfilippo syndrome Type A and frontotemporal dementia, with collaborations with the FDA and Takeda, respectively [4][5] Financial Performance - For Q1 2025, Denali reported a net loss of $133.0 million, an increase from a net loss of $101.8 million in Q1 2024 [10] - Research and development expenses rose to $116.2 million in Q1 2025 from $107.0 million in Q1 2024, primarily due to increased spending on clinical and preclinical programs [11] - General and administrative expenses increased to $29.4 million in Q1 2025 from $25.2 million in Q1 2024, driven by activities related to the BLA submission for tividenofusp alfa [14] Clinical Program Updates - The BLA submission for tividenofusp alfa is based on data from a Phase 1/2 study involving 47 participants, with the FDA's review process now initiated [3] - Denali is conducting a global Phase 2/3 COMPASS study to support regulatory approvals for tividenofusp alfa [3] - The company is also advancing DNL126 for Sanfilippo syndrome Type A, with ongoing discussions with the FDA for an accelerated development path [4] Corporate Developments - Denali has launched a clinical biomanufacturing facility in Salt Lake City, enhancing its manufacturing capabilities and supply chain control [9] - The company is actively participating in several upcoming investor conferences to engage with stakeholders and present its developments [13]

WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update. "In the first quarter we again delivered excellent performance driven by strong demand growth for our ZORYVE portfolio, which offers a distinct and compelling value proposition and provides h ...

BARTLETT, Tenn., May 6, 2025 /PRNewswire/ -- SurgePays, Inc. (NASDAQ: SURG) ("SurgePays" or the "Company"), a wireless and point-of-sale technology company, will release its first quarter 2025 financial results, after the close of trading on Tuesday, May 13, 2025. On the same day, at 5:00 p.m. ET, management will host a conference call to discuss its financial results.The live webcast of the call can be accessed on the Company's investor relations website at ir.surgepays.com, or by registering at the follow ...

YORK, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- The York Water Company's (NASDAQ:YORW) President, JT Hand, announced the Company's financial results for the first quarter of 2025. President Hand reported that first quarter operating revenues of $18,456,000 increased $828,000, but net income of $3,638,000 decreased $689,000 compared to the first quarter of 2024. Basic and Diluted Earnings per share of $0.25 for the three-month period decreased $0.05 compared to the same period last year. Increased revenues were ...

Company to Host Conference Call, May 13, 2025 at 4:30 p.m. ETSAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, will release its financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. Management will then host a webcast and conference call at 4:30 p.m. ET on May 13. Title:Capricor Therapeutics First Qu ...